AZN - Why AstraZeneca and Surface Oncology Rose Today
AstraZeneca (NASDAQ: AZN) and Surface Oncology (NASDAQ: SURF) shares both traded up on Monday, bucking the heavily bearish trend of the overall stock market. AstraZeneca closed the day more than 5% higher on the back of positive news about its cancer drug, while Surface Oncology slipstreamed behind it with a 3.2% gain.
On Saturday, AstraZeneca provided an update about the phase 3 trial of its Imfinzi oncology drug in combination therapy for the treatment of one type of lung cancer.
The company said that, when administered with certain chemotherapies, Imfinzi "demonstrated a sustained, clinically meaningful overall survival (OS) benefit at three years for adults with extensive-stage small cell lung cancer (ES-SCLC) treated in the first-line setting."
For further details see:
Why AstraZeneca and Surface Oncology Rose Today